0.237  -0.005 (-2.07%)		12-01 16:00
Open: 0.2585 High: 0.2585 Volume: 109,107		Pre. Close: 0.242 Low: 0.2265 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	0.35	1-year :	0.43
Resists	First :	0.3	Second :	0.37
Pivot price	0.24
Supports	First :	0.18	Second :	0.15
MAs	MA(5) :	0.24	MA(20) :	0.25
	MA(100) :	0.45	MA(250) :	0.82
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	32.9	D(3) :	26.2
RSI	RSI(14): 43.6
52-week	High :	1.94	Low :	0.18

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed above bottom band by 35.0%. Bollinger Bands are 70.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.26 - 0.26	0.26 - 0.26
Low:	0.22 - 0.22	0.22 - 0.23
Close:	0.23 - 0.24	0.24 - 0.24

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Wed, 29 Nov 2023
Is Genprex Inc (GNPX) Stock a Bad Value? - InvestorsObserver

Thu, 23 Nov 2023
Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer - Yahoo Finance

Fri, 17 Nov 2023
North American Morning Briefing: Stock Futures -2- - Morningstar

Wed, 04 Oct 2023
Genprex to Present Data on the Use of REQORSA® for the ... - PR Newswire

Thu, 21 Sep 2023
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation ... - BioSpace

Mon, 04 Sep 2023
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	59 (M)
Held by Insiders	2.3 (%)
Held by Institutions	15.8 (%)
Shares Short	1,640 (K)
Shares Short P.Month	1,650 (K)

EPS	-0.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-85 %
Return on Equity (ttm)	-158.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.54
Qtrly Earnings Growth	0 %
Operating Cash Flow	-24 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-0.39
PEG Ratio	0
Price to Book value	1.12
Price to Sales	0
Price to Cash Flow	-0.58

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.